Synonym
NCX-530; NCX530; NCX 530; NO-indomethacin; NO indomethacin; NOindomethacin;
IUPAC/Chemical Name
3-((nitrooxy)methyl)phenyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate
InChi Key
CDBYEQYEPGILFF-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H21ClN2O7/c1-16-22(14-25(30)36-21-5-3-4-17(12-21)15-35-29(32)33)23-13-20(34-2)10-11-24(23)28(16)26(31)18-6-8-19(27)9-7-18/h3-13H,14-15H2,1-2H3
SMILES Code
COC1=CC2=C(N(C(C3=CC=C(Cl)C=C3)=O)C(C)=C2CC(OC4=CC(CO[N+]([O-])=O)=CC=C4)=O)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
508.91
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ragot T, Provost C, Prignon A, Cohen R, Lepoivre M, Lausson S. Apoptosis induction by combination of drugs or a conjugated molecule associating non- steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: implication of the tumor suppressor p73. Thyroid Res. 2015 Aug 14;8:13. doi: 10.1186/s13044-015-0025-3. PMID: 26273323; PMCID: PMC4535850.
2: Kawaratani Y, Harada T, Hirata Y, Nagaoka Y, Tanimura S, Shibano M, Taniguchi M, Yasuda M, Baba K, Uesato S. New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group. Bioorg Med Chem. 2011 Jul 1;19(13):3995-4003. doi: 10.1016/j.bmc.2011.05.031. Epub 2011 May 23. PMID: 21664138.
3: Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther. 2006 Jun;5(6):1530-8. doi: 10.1158/1535-7163.MCT-06-0061. PMID: 16818512.
4: Tomisato W, Tanaka K, Tsutsumi S, Hoshino T, Yokomizo K, Suzuki K, Katsu T, Mizushima T, Mizushima T. Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. Dig Dis Sci. 2005 Oct;50(10):1927-37. doi: 10.1007/s10620-005-2963-4. PMID: 16187199.
5: Takeuchi K, Mizoguchi H, Araki H, Komoike Y, Suzuki K. Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals. Dig Dis Sci. 2001 Aug;46(8):1805-18. doi: 10.1023/a:1010638528675. PMID: 11508687.
6: Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther. 2001 Feb;15(2):257-67. doi: 10.1046/j.1365-2036.2001.00916.x. PMID: 11148446.